Edwards KH - Search Results

1

Prediction of poor mobilization of autologous CD34+ cells with growth factor in multiple myeloma patients: implications for risk-stratification.

Costa LJ, Nista EJ, Buadi FK, Lacy MQ, Dispenzieri A, Kramer CP, Edwards KH, Kang Y, Gertz MA, Stuart RK, Kumar S. Costa LJ, et al. Among authors: edwards kh. Biol Blood Marrow Transplant. 2014 Feb;20(2):222-8. doi: 10.1016/j.bbmt.2013.11.003. Epub 2013 Nov 6. Biol Blood Marrow Transplant. 2014. PMID: 24211319 Free article.

2

Schade H, Chhabra S, Kang Y, Stuart RK, Edwards KH, Kramer C, Butcher C, Littleton A, Schneider M, Budisavljevic MN, Costa LJ. Schade H, et al. Among authors: edwards kh. Transfusion. 2014 Dec;54(12):3131-7. doi: 10.1111/trf.12761. Epub 2014 Jun 19. Transfusion. 2014. PMID: 24947954 Clinical Trial.

3

Effectiveness, Safety, and Cost Implications of Outpatient Autologous Hematopoietic Stem Cell Transplant for Multiple Myeloma.

Marini J, Maldonado A, Weeda E, Neppalli A, Hashmi H, Edwards K. Marini J, et al. Hematol Oncol Stem Cell Ther. 2023 May 23;16(4):351-357. doi: 10.56875/2589-0646.1038. Hematol Oncol Stem Cell Ther. 2023. PMID: 37363969

4

Evaluation of electronic health record implementation on pharmacist interventions related to oral chemotherapy management.

Finn A, Bondarenka C, Edwards K, Hartwell R, Letton C, Perez A. Finn A, et al. J Oncol Pharm Pract. 2017 Dec;23(8):563-574. doi: 10.1177/1078155216665247. Epub 2016 Aug 29. J Oncol Pharm Pract. 2017. PMID: 27573921

5

Real-World Experience and Optimization of Outpatient Chimeric Antigen Receptor T Cell Therapy.

McGann M, Davis JA, Gaffney KJ, Smith D, Edwards K, Hess BT, Hashmi H. McGann M, et al. Transplant Cell Ther. 2022 Sep;28(9):583-585. doi: 10.1016/j.jtct.2022.06.021. Epub 2022 Jun 30. Transplant Cell Ther. 2022. PMID: 35781100 Free article. No abstract available.

6

Fever Characteristics and Impact on Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy.

Davis JA, Gaffney KJ, McGann M, Smith D, Edwards K, Baldino E, Bakos K, Butcher C, Greenwell B, Hess BT, Hashmi H. Davis JA, et al. Clin Lymphoma Myeloma Leuk. 2023 Jan;23(1):e14-e18. doi: 10.1016/j.clml.2022.09.005. Epub 2022 Oct 7. Clin Lymphoma Myeloma Leuk. 2023. PMID: 36319568 Review.

7

Early versus standard management of chimeric antigen receptor therapy toxicities and management's impact on safety and efficacy.

Gaffney KJ, Davis JA, McGann M, Edwards K, Ahmed Z, Butcher C, Greenwell B, Hess BT, Hashmi H. Gaffney KJ, et al. J Oncol Pharm Pract. 2024 Jan;30(1):151-158. doi: 10.1177/10781552231170757. Epub 2023 Apr 25. J Oncol Pharm Pract. 2024. PMID: 37097891

8

The incidence and characteristics of VTE within 100 days of CAR T-cell therapy.

Gaffney KJ, McGann M, Davis JA, Edwards KH, Hashmi H. Gaffney KJ, et al. Among authors: edwards kh. Ann Hematol. 2023 Mar;102(3):683-685. doi: 10.1007/s00277-023-05104-w. Epub 2023 Jan 19. Ann Hematol. 2023. PMID: 36658372 No abstract available.

9

Requesting air ambulance transport of patients with suspected appendicitis: The decision-making process through the eyes of the rural clinician.

Edwards KH, Franklin RC, Edwards MT, Stewart RA. Edwards KH, et al. Aust J Rural Health. 2023 Jun;31(3):426-435. doi: 10.1111/ajr.12956. Epub 2022 Dec 21. Aust J Rural Health. 2023. PMID: 36541830

10

Using a Quality Framework to Explore Air Ambulance Patients' Journey Outcomes in Central Queensland, Australia.

Edwards KH, Franklin RC, Jones R, Kuhnert PM, Khanna S. Edwards KH, et al. Prehosp Disaster Med. 2022 Nov 11:1-8. doi: 10.1017/S1049023X22001480. Online ahead of print. Prehosp Disaster Med. 2022. PMID: 36366838

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

23 results

Search Page